Galectin Therapeutics Hosted International Conference on Galectins and Disease

Published: Sep 20, 2012

NEWTON, Mass.--(BUSINESS WIRE)--Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced the proceedings of an international galectin meeting, hosted by Galectin Therapeutics and held at the Harvard Club in Boston, MA, on September 17-19, has been accepted for publication by the American Chemical Society. The book, entitled “Galectins and Disease: Implications for Targeted Therapeutics”, is expected to be published in early 2013 and is edited by Dr. Anatole A. Klyosov, Chief Scientist and Founder, and Dr. Peter G. Traber, President, Chief Executive Officer and Chief Medical Officer, both of Galectin Therapeutics.

Back to news